Health Condition 1: C793- Secondary malignant neoplasm of brain and cerebral meninges
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
NIL
Eligibility
Inclusion criteria
Inclusion criteria: Triple Negative Breast Cancer Patients with brain metastasis
Exclusion criteria
Exclusion criteria: Patients not willing to sign the informed consent form (Prospective part of study)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study involves the development of patient-derived organoid models from clinical samples of individuals diagnosed with a specific subtype of breast cancer. The objective is to establish and characterize three-dimensional organoid systems derived from metastatic brain sites from primary breast tumor. The organoid platform will be leveraged to explore therapeutic sensitivities, with the broader goal of informing strategies for metastasis tumor growth from primary site.Timepoint: 24 months after surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary aims of this study include the evaluation of organoid responses to conventional therapeutic agents, with the goal of identifying treatment patterns that may correlate with clinical outcomes. The organoid system will further serve as a platform to evaluate the feasibility of targeted delivery strategies across the blood-brain barrier.Timepoint: 36 months after surgery | — |
Countries
India
Contacts
Public ContactDr Puja Sandbhor
ACTREC, Tata Memorial Centre
Outcome results
None listed